{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Prostate+Cancer&page=5", "query": { "condition": "Small Cell Prostate Cancer", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 222, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Prostate+Cancer&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Prostate+Cancer&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T10:57:01.949Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02009449", "title": "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Prostate Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Pancreatic Carcinoma", "Non-small Cell Lung Carcinoma", "Solid Tumors", "Breast Cancer" ], "interventions": [ { "name": "Pegilodecakin", "type": "DRUG" }, { "name": "Paclitaxel or Docetaxel and Carboplatin or Cisplatin", "type": "DRUG" }, { "name": "FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)", "type": "DRUG" }, { "name": "gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "Gemcitabine/carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 353, "start_date": "2013-11-15", "completion_date": "2023-07-22", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009449" }, { "nct_id": "NCT06784193", "title": "Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)", "Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Metastatic Breast Cancer", "Fulvestrant", "Palazestrant" ], "interventions": [ { "name": "OP-3136", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Palazestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2024-12-16", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 13, "location_summary": "Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06784193" }, { "nct_id": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer", "Additional Indications Below for Module 4 and 5", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Bladder Cancer", "Gastric Cancer", "Biliary Cancer", "Cervical Cancer", "Endometrial Cancer", "Small Cell Lung Cancer Only in Module 5" ], "interventions": [ { "name": "AZD5305", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "T- Dxd", "type": "DRUG" }, { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Camizestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 702, "start_date": "2020-11-12", "completion_date": "2027-05-28", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644068" }, { "nct_id": "NCT00629876", "title": "A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Peginesatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 2, "start_date": "2008-01", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2011-12-01", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Corpus Christi, Texas", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Corpus Christi", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00629876" }, { "nct_id": "NCT03452774", "title": "SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer, Metastatic", "Cancer", "Cancer of Pancreas", "Cancer of Liver", "Cancer of Stomach", "Cancer Liver", "Cancer of Rectum", "Cancer of Kidney", "Cancer of Esophagus", "Cancer of Cervix", "Cancer of Colon", "Cancer of Larynx", "Cancer, Lung", "Cancer, Breast", "Cancer, Advanced", "Cancer Prostate", "Cancer of Neck", "Cancer of Skin", "Neuroendocrine Tumors", "Carcinoma", "Mismatch Repair Deficiency", "BRCA Gene Rearrangement", "Non Hodgkin Lymphoma", "Leukemia", "Non Small Cell Lung Cancer", "Cholangiocarcinoma", "Glioblastoma", "Central Nervous System Tumor", "Melanoma", "Urothelial Carcinoma", "Bladder Cancer", "Ovarian Cancer", "Endometrial Cancer", "Testicular Cancer", "Breast Cancer", "COVID", "Myelofibrosis", "Myeloproliferative Neoplasm", "Myeloproliferative Disorders", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Clinical Trial Matching", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massive Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50000, "start_date": "2018-01-01", "completion_date": "2040-06", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452774" }, { "nct_id": "NCT03351140", "title": "Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Qualitative Interviews", "type": "OTHER" }, { "name": "PROMIS Physical Function Items", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2017-12-20", "completion_date": "2020-05-08", "has_results": false, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 1, "location_summary": "Mountlake Terrace, Washington", "locations": [ { "city": "Mountlake Terrace", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03351140" }, { "nct_id": "NCT00078845", "title": "Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Neurotoxicity", "Ovarian Cancer", "Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Amifostine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2004-05", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2012-10-17", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 15, "location_summary": "Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more", "locations": [ { "city": "Decatur", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Alexandria", "state": "Louisiana" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078845" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT02552121", "title": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovary Cancer", "Cervix Cancer", "Endometrium Cancer", "Bladder Cancer", "Prostate Cancer (CRPC)", "Esophagus Cancer", "Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Tisotumab vedotin (HuMax-TF-ADC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2015-11-30", "completion_date": "2017-12-13", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02552121" }, { "nct_id": "NCT03910660", "title": "A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Neuroendocrine Tumors", "Small Cell Carcinoma" ], "interventions": [ { "name": "BXCL701 plus Pembrolizumab", "type": "DRUG" }, { "name": "BXCL701 monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioXcel Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 98, "start_date": "2019-02-12", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-28T10:57:01.949Z", "location_count": 9, "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03910660" } ] }